What's the difference between Liraglutide and Dulaglutide?

Liraglutide (Saxenda/Victoza) is a daily injection requiring 7 injections per week. Dulaglutide (Trulicity) is a weekly injection requiring only 1 injection per week. Dulaglutide uses an Fc fusion protein technology that extends its half-life, allowing for less frequent dosing while maintaining therapeutic effect.

Which GLP-1 has the best cardiovascular outcomes data?

Liraglutide (LEADER trial) was the first GLP-1 to demonstrate significant cardiovascular benefit, reducing MACE by 13%. Dulaglutide (REWIND trial) also showed CV benefit with 12% reduction in MACE. Both preceded semaglutide's CVOT data. However, tirzepatide has shown the strongest CV risk reduction to date in SURPASS-CVOT.

Why do some patients still choose Liraglutide or Dulaglutide over semaglutide?

Three main reasons: (1) Insurance coverage — older GLP-1s often have better formulary coverage with lower copays; (2) Side effect profile — some patients tolerate these better than semaglutide; (3) Availability — these are more widely stocked at pharmacies compared to ongoing supply constraints with newer GLP-1s.

How much weight loss can I expect with Liraglutide?

The SCALE trials showed approximately 8% average weight loss at 56 weeks with liraglutide 3mg daily, combined with diet and exercise. This is less than semaglutide (14.9%) and tirzepatide (22.5%), but remains clinically meaningful for obesity management.

Is Dulaglutide FDA-approved for weight loss?

No. Dulaglutide (Trulicity) is FDA-approved only for type 2 diabetes management, not for chronic weight loss. Saxenda (liraglutide 3mg) is FDA-approved for weight management. This is a key distinction — tirzepatide (Zepbound) and semaglutide (Wegovy) have both obesity and diabetes indications.

Liraglutide & Dulaglutide: Established GLP-1 Agonists Comparison (2026)

How GLP-1 Agonists Work

The Incretin Pathway

🧬

GLP-1 Receptor Activation

GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone released from the gut after eating. It enhances insulin secretion, suppresses glucagon, and slows gastric emptying to promote satiety.

🍽️

Appetite Suppression

GLP-1 agonists activate hypothalamic receptors that reduce hunger and food noise. Users report feeling fuller faster and having less craving for high-calorie foods.

⏱️

Slowed Gastric Emptying

By delaying stomach emptying, GLP-1 agonists extend the feeling of fullness after meals, reducing overall caloric intake throughout the day.

🏃

Beta Cell Preservation

GLP-1 agonists enhance pancreatic beta cell function and may protect against beta cell apoptosis, offering disease-modifying potential in type 2 diabetes.

Liraglutide

Saxenda / Victoza

The original FDA-approved weight management GLP-1 agonist. Daily injection with proven long-term outcomes.

Average Weight Loss (SCALE Trials)

56 weeks, 3mg daily dose + lifestyle intervention

~8%

💉

Daily Injection

Requires daily subcutaneous injection. Some users prefer the routine consistency; others find weekly options more convenient.

❤️

LEADER Trial (CV Benefit)

First GLP-1 to demonstrate cardiovascular benefit. 13% reduction in major adverse cardiovascular events (MACE) over 3.8 years.

✅

Dual FDA Approval

Approved for both type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014) — the first GLP-1 to achieve both.

📊

SCALE Trial Data

SCALE Obesity & Prediabetes: 8.4% weight loss at 56 weeks. SCALE Maintenance: 6.2% vs placebo 1.8% with lifestyle counseling.

💉 Liraglutide Dosing Schedule (Saxenda)

1 Week 1-2: 0.6mg daily (starting dose)

2 Week 3-4: 1.2mg daily (first escalation)

3 Week 5-6: 1.8mg daily (second escalation)

4 Week 7+: 2.4mg daily (third escalation if tolerated)

5 Max: 3.0mg daily (maintenance dose)

Dulaglutide

Trulicity

Weekly GLP-1 injection using Fc fusion technology for extended half-life. Primarily diabetes-focused with strong CV data.

A1C Reduction (AWARD Trials)

Type 2 diabetes, 52 weeks, 1.5mg weekly

-1.5%

🔬

Fc Fusion Technology

Dulaglutide combines two GLP-1 analog molecules with an Fc fragment, creating a large molecule with a 5-day half-life enabling weekly dosing.

📅

Weekly Convenience

Single weekly injection provides full therapeutic effect. Less injection burden than daily liraglutide, though not approved for weight loss indication.

❤️

REWIND Trial (CV Benefit)

12% reduction in MACE cardiovascular events. Notably, REWIND enrolled more patients with lower baseline cardiovascular risk than other GLP-1 CVOTs.

⚠️

Weight Loss Indication?

Trulicity is NOT approved for weight management — only type 2 diabetes. This is a key distinction vs Saxenda (liraglutide) and Wegovy (semaglutide).

💉 Dulaglutide Dosing Schedule (Trulicity)

1 Week 1-4: 0.75mg weekly (starting dose)

2 Week 5+: 1.5mg weekly (standard maintenance)

3 Higher doses (3mg, 4.5mg) available for enhanced glycemic control

Head-to-Head

GLP-1 Agonist Comparison

Comparing all four major GLP-1 based therapies: Liraglutide, Dulaglutide, Semaglutide, and Tirzepatide.

Drug	Dosing	Weight Loss	A1C Reduction	CV Benefit	Obesity Approval	Monthly Cost*
Daily Liraglutide	Daily	~8%	-1.2%	13% (LEADER)	✅ Yes (Saxenda)	$1,000-1,350
Weekly Dulaglutide	Weekly	~3-4%	-1.5%	12% (REWIND)	❌ No	$850-1,000
Weekly Semaglutide	Weekly	~15%	-1.8%	15% (SELECT)	✅ Yes (Wegovy)	$1,350-1,700
New Tirzepatide	Weekly	~22%	-2.4%	17% (SURPASS)	✅ Yes (Zepbound)	$1,000-1,200

*WAC pricing — actual cost depends on insurance coverage and formulary tier.

Why Newer GLP-1s Dominate

Why Semaglutide & Tirzepatide Took Over

📈

Superior Efficacy

Tirzepatide (22.5%) dramatically outperforms liraglutide (8%) and dulaglutide (3-4%) in weight loss. Even semaglutide (15%) nearly doubles liraglutide's results.

💉

Better Dosing Convenience

Weekly semaglutide and tirzepatide beat daily liraglutide on convenience. Only one injection weekly vs 7 for daily drugs — dramatically improves adherence.

💊

Oral Option Exists

Semaglutide is available as oral Rybelsus — the only oral GLP-1. No other GLP-1 on this list offers a pill alternative for those with needle aversion.

🏆

Latest CV Data

Tirzepatide's SURPASS-CVOT showed 17% CV risk reduction — the strongest cardiovascular outcome of any GLP-1 agonist to date, surpassing LEADER and REWIND.

When to Choose Established GLP-1s

Why Older GLP-1s Are Still Right for Some

These drugs aren't obsolete. For many patients, liraglutide or dulaglutide remain excellent choices based on individual circumstances. The "best" GLP-1 is the one that works for your specific situation.

🏥

Insurance & formulary

Older GLP-1s often have better insurance coverage with lower copays. If your formulary prefers liraglutide or dulaglutide, these can be $30-50/month vs $350+ for newer drugs.

🏪

Availability

Supply constraints have affected Wegovy and Zepbound. Liraglutide and dulaglutide have more stable supply chains and are more readily available at local pharmacies.

🤢

Side Effect Tolerance

Some patients tolerate liraglutide's gradual daily dosing better than weekly high-dose semaglutide. More titratable with smaller dose increments can reduce GI side effects.

💊

Diabetes-Only Indication

For patients with type 2 diabetes who don't need weight loss medication, dulaglutide provides excellent glycemic control without the "weight loss drug" label or costs.

Safety Profile

Side Effects & Warnings

Liraglutide Common Side Effects

Nausea44%

Diarrhea30%

Constipation20%

Vomiting16%

Dulaglutide Common Side Effects

Nausea21%

Diarrhea18%

Vomiting10%

Ideal Candidates

Who Should Consider These GLP-1s?

✅ Great Fit For

Patients with type 2 diabetes seeking glycemic control
Those with insurance that covers liraglutide/dulaglutide
Patients experiencing supply issues with semaglutide/tirzepatide
Those preferring daily routine for consistency
Patients who tolerate higher-dose weekly GLP-1s poorly
Anyone needing a gradual titratable approach

⚠️ Consider Other Options

Patients prioritizing maximum weight loss results
Those wanting once-weekly dosing convenience
Patients needing obesity-specific indication
Those wanting oral medication option (semaglutide)
Anyone with contraindications to GLP-1 class

References

Key Clinical Trials

LEADER Trial

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso SP, et al. NEJM 2016; 375(4): 311-322 · PMID: 27295427

PMID: 27295427

REWIND Trial

Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes

Gerstein HC, et al. Lancet 2019; 394(10193): 121-130 · PMID: 31189532

PMID: 31189532

SCALE Trials

Liraglutide for Weight Management in Overweight and Obese Adults

Pi-Sunyer X, et al. NEJM 2015; 373(1): 11-22 · PMID: 26132939

PMID: 26132939

AWARD Trials

Dulaglutide Efficacy in Type 2 Diabetes (Multiple AWARD Studies)

Jendle J, et al. Diabetes Obes Metab 2016; 18(4): 425-429

PMID: 26872654

⚠️ Medical Disclaimer

This content is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or modifying any medication or supplementation protocol. GLP-1 agonists carry risks including pancreatitis, thyroid tumors, and severe gastrointestinal events. Individual results vary based on diet, exercise, genetics, and other factors.

The Incretin Pathway

Saxenda / Victoza

Trulicity

GLP-1 Agonist Comparison

Why Semaglutide & Tirzepatide Took Over

Why Older GLP-1s Are Still Right for Some

Side Effects & Warnings

Liraglutide Common Side Effects

Dulaglutide Common Side Effects

Who Should Consider These GLP-1s?

Key Clinical Trials

🛒 Related Products

🔗 Related Research

Semaglutide Research Results

Tirzepatide Results

Tirzepatide vs Semaglutide

GLP-1 Muscle Loss Prevention

Best Peptides for Weight Loss

Semaglutide Calculator

⚠️ Medical Disclaimer